Literature DB >> 7547247

p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs.

R D Malcomson1, M Oren, A H Wyllie, D J Harrison.   

Abstract

Many recent studies have implicated p53 in the cellular response to injury and induction of cell death by apoptosis. In a rat embryonal fibroblast cell line transformed with c-Ha-ras and a mutant temperature-sensitive p53 (val135), cells were G1 arrested at the permissive temperature of 32 degrees C when overexpressed p53 was in wild-type conformation. In this state cells were resistant to apoptosis induced by etoposide (at up to 50 microM) or bleomycin (15 microU ml-1). Cells at 37 degrees C with overexpressed p53 in mutant conformation were freed from this growth arrest, continued proliferating and showed dose-dependent increases in apoptosis. This death is independent of wild-type p53 function. Control cells containing a non-temperature-sensitive mutant p53 (phe132) were sensitive to both etoposide and bleomycin after 24 h at 32 degrees C and 37 degrees C, indicating that the results are not simply due to temperature effects on pharmacokinetics or DNA damage. Our data show that induction of a stable p53-mediated growth arrest renders these cells much less likely to undergo apoptosis in response to certain anti-cancer drugs, and we conclude that the regulatory role of p53 in apoptosis is influenced by the particular cellular context in which this gene is expressed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547247      PMCID: PMC2034034          DOI: 10.1038/bjc.1995.440

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  48 in total

Review 1.  Cell death in health and disease: the biology and regulation of apoptosis.

Authors:  C O Bellamy; R D Malcomson; D J Harrison; A H Wyllie
Journal:  Semin Cancer Biol       Date:  1995-02       Impact factor: 15.707

Review 2.  Lymphocyte apoptosis--mechanisms and implications in disease.

Authors:  S E Howie; D J Harrison; A H Wyllie
Journal:  Immunol Rev       Date:  1994-12       Impact factor: 12.988

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  Preferential damage of active chromatin by bleomycin.

Authors:  M T Kuo
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

5.  Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro.

Authors:  Y S Bae; I Kawasaki; H Ikeda; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.

Authors:  W E Mercer; M T Shields; M Amin; G J Sauve; E Appella; J W Romano; S J Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

7.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.

Authors:  A J Wagner; J M Kokontis; N Hay
Journal:  Genes Dev       Date:  1994-12-01       Impact factor: 11.361

Review 8.  Molecular mechanisms of drug resistance in tumours.

Authors:  D J Harrison
Journal:  J Pathol       Date:  1995-01       Impact factor: 7.996

9.  The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae.

Authors:  T A Weinert; L H Hartwell
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

10.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis.

Authors:  L L Vindeløv; I J Christensen; N I Nissen
Journal:  Cytometry       Date:  1983-03
View more
  12 in total

Review 1.  Apoptosis: molecular mechanisms and implications for cancer chemotherapy.

Authors:  H J Guchelaar; A Vermes; I Vermes; C Haanen
Journal:  Pharm World Sci       Date:  1997-06

2.  Anti-apoptotic activity of low levels of wild-type p53.

Authors:  P Lassus; M Ferlin; J Piette; U Hibner
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

3.  A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.

Authors:  R E Barrington; M A Subler; E Rands; C A Omer; P J Miller; J E Hundley; S K Koester; D A Troyer; D J Bearss; M W Conner; J B Gibbs; K Hamilton; K S Koblan; S D Mosser; T J O'Neill; M D Schaber; E T Senderak; J J Windle; A Oliff; N E Kohl
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

4.  Transcription abnormalities potentiate apoptosis of normal human fibroblasts.

Authors:  L Andera; B Wasylyk
Journal:  Mol Med       Date:  1997-12       Impact factor: 6.354

5.  Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA--in vitro and in vivo studies.

Authors:  Y Liao; Z Y Tang; K D Liu; S L Ye; Z Huang
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation.

Authors:  J Lamb; D N Wheatley
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

7.  Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.

Authors:  M Trepel; P Groscurth; U Malipiero; E Gulbins; J Dichgans; M Weller
Journal:  J Neurooncol       Date:  1998-08       Impact factor: 4.130

8.  Apoptosis after gamma irradiation. Is it an important cell death modality?

Authors:  E Siles; M Villalobos; L Jones; R Guerrero; J J Eady; M T Valenzuela; M I Núñez; T J McMillan; J M Ruiz de Almodóvar
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

9.  Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target.

Authors:  C A Hall-Jackson; T Jones; N G Eccles; T P Dawson; J A Bond; A Gescher; D Wynford-Thomas
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

10.  3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.

Authors:  S R Wedge; J K Porteous; E S Newlands
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.